Developing Care Plans for Treatment-based Patient Monitoring in Relapsed/Refractory Multiple Myeloma

Please Log In or Register to continue.

Release Date: August 23, 2017
Expiration Date: August 23, 2018

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Due to the increasing number of new treatment options for patients with relapsed/refractory multiple myeloma (RRMM), nurses must understand the key facets of patient monitoring required for development of care plans. In this activity, participants will learn about the major treatment-related adverse events and other critical aspects of patient monitoring, which must be incorporated into care plans for patients with RRMM being treated with the new drug regimens. In addition, there will be discussion of when and how to intervene for various events that may occur upon routine assessment and monitoring of patients receiving these agents.

Target Audience

This activity is designed for nurses who have an interest in enhancing their clinical skills in multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the patient monitoring strategies associated with the new drug regimens in relapsed/refractory multiple myeloma (RRMM)
  • Recognize the role of nurses in routine monitoring for drug-related toxicity and other events that may occur in patients with RRMM
  • Explain intervention strategies for events that may occur during patient monitoring, including non-pharmacologic management of treatment-related toxicities

Agenda

Developing Care Plans for Treatment-based Patient Monitoring in Relapsed/Refractory Multiple Myeloma – Beth Faiman, PhD, MSN, APRN-BC, AOCN®

Instructions for Participation and Credit

This activity is eligible for credit through August 23, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biography

Beth Faiman, PhD, MSN, APRN-BC, AOCN®
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Dr. Beth Faiman received her bachelor of science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio. She received a master of science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio, and a PhD in Clinical Research and Nursing from Case Western Reserve University. Dr. Faiman holds an advanced oncology nurse certification through Oncology Nursing Certification Corporation (ONCC). She is an Adult Nurse Practitioner in the Department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic in Cleveland, Ohio, and adjunct faculty at Ursuline College, Case Western Reserve University and Kent State University.

Dr. Faiman is an active author, presenter, and educator on the topic of multiple myeloma, chronic lymphocytic leukemia, plasma cell dyscrasias, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. She is an appointed delegate on the International Myeloma Foundation Nurse Leadership Board. Dr. Faiman is currently editor-in-chief of The Oncology Nurse APN/PA, and is on the editorial board of ASH Clinical News, among others. She has edited several books, authored many chapters, and written numerous articles relating to the diagnosis and treatment of multiple myeloma, treatment adherence, pain, palliation, and cancer symptom management. Dr. Faiman received the 2015 Dean’s Legacy Award for PhD Studies from Case Western Reserve University, and was named the Leukemia and Lymphoma Society’s Woman of the Year for Cleveland and Akron Ohio, 2016.

Accreditation

MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 17-163-063

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Beth Faiman has received honoraria related to speakers’ bureau activities and as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, and Takeda Oncology.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.